Silco Pharmaceuticals Limited (DSE: SILCOPHL)
Bangladesh
· Delayed Price · Currency is BDT 16.70
+0.10 (0.60%)
At close: Dec 19, 2024
Silco Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | 2018 - 2014 |
| Revenue | - | 464.7 | 559.47 | 601.06 | 733.65 | 919.04 | Upgrade
|
| Revenue Growth (YoY) | - | -16.94% | -6.92% | -18.07% | -20.17% | 0.14% | Upgrade
|
| Cost of Revenue | - | 318.76 | 372.72 | 433.3 | 521.74 | 639.31 | Upgrade
|
| Gross Profit | - | 145.93 | 186.75 | 167.76 | 211.92 | 279.73 | Upgrade
|
| Selling, General & Admin | - | 69.74 | 80.98 | 80.09 | 110.23 | 138.26 | Upgrade
|
| Other Operating Expenses | - | -0 | -0 | -0 | -0 | -0 | Upgrade
|
| Operating Expenses | - | 78.75 | 89.27 | 88.37 | 114.95 | 138.26 | Upgrade
|
| Operating Income | - | 67.18 | 97.48 | 79.39 | 96.96 | 141.47 | Upgrade
|
| Interest Expense | - | -0.2 | -0.53 | -0.76 | - | - | Upgrade
|
| Interest & Investment Income | - | 0.4 | 0.32 | 6.12 | 14.58 | 0.73 | Upgrade
|
| Other Non Operating Income (Expenses) | - | 3.3 | 5.21 | 4.46 | -0.64 | -0.4 | Upgrade
|
| EBT Excluding Unusual Items | - | 70.69 | 102.48 | 89.21 | 110.9 | 141.8 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 18.56 | 6.48 | 0.42 | - | - | Upgrade
|
| Pretax Income | - | 89.24 | 108.96 | 89.63 | 110.9 | 141.8 | Upgrade
|
| Income Tax Expense | - | 20.02 | 24.51 | 4.98 | 27.73 | -20.69 | Upgrade
|
| Net Income | - | 69.22 | 84.45 | 84.65 | 83.18 | 162.48 | Upgrade
|
| Net Income to Common | - | 69.22 | 84.45 | 84.65 | 83.18 | 162.48 | Upgrade
|
| Net Income Growth | - | -18.03% | -0.23% | 1.77% | -48.81% | 54.21% | Upgrade
|
| Shares Outstanding (Basic) | 101 | 104 | 104 | 104 | 104 | 81 | Upgrade
|
| Shares Outstanding (Diluted) | 101 | 104 | 104 | 104 | 104 | 81 | Upgrade
|
| Shares Change (YoY) | -2.81% | - | - | - | 28.88% | 13.76% | Upgrade
|
| EPS (Basic) | - | 0.67 | 0.81 | 0.82 | 0.80 | 2.02 | Upgrade
|
| EPS (Diluted) | - | 0.67 | 0.81 | 0.82 | 0.80 | 2.02 | Upgrade
|
| EPS Growth | - | -18.03% | -0.23% | 1.77% | -60.28% | 35.56% | Upgrade
|
| Free Cash Flow | - | -1.47 | 62.95 | -119.22 | -23.45 | 5.28 | Upgrade
|
| Free Cash Flow Per Share | - | -0.01 | 0.61 | -1.15 | -0.23 | 0.07 | Upgrade
|
| Dividend Per Share | - | 0.300 | 0.500 | 1.000 | 1.000 | 0.182 | Upgrade
|
| Dividend Growth | - | -40.00% | -50.00% | 0% | 450.06% | - | Upgrade
|
| Gross Margin | - | 31.40% | 33.38% | 27.91% | 28.88% | 30.44% | Upgrade
|
| Operating Margin | - | 14.46% | 17.42% | 13.21% | 13.22% | 15.39% | Upgrade
|
| Profit Margin | - | 14.90% | 15.09% | 14.08% | 11.34% | 17.68% | Upgrade
|
| Free Cash Flow Margin | - | -0.32% | 11.25% | -19.83% | -3.20% | 0.57% | Upgrade
|
| EBITDA | - | 153.9 | 172.16 | 153.98 | 175.65 | 223.93 | Upgrade
|
| EBITDA Margin | - | 33.12% | 30.77% | 25.62% | 23.94% | 24.37% | Upgrade
|
| D&A For EBITDA | - | 86.72 | 74.68 | 74.59 | 78.69 | 82.47 | Upgrade
|
| EBIT | - | 67.18 | 97.48 | 79.39 | 96.96 | 141.47 | Upgrade
|
| EBIT Margin | - | 14.46% | 17.42% | 13.21% | 13.22% | 15.39% | Upgrade
|
| Effective Tax Rate | - | 22.44% | 22.49% | 5.56% | 25.00% | - | Upgrade
|
| Advertising Expenses | - | 3.79 | 4.84 | 6.2 | 12.07 | 15.95 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.